QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 限定条件 专题：复旦大学上海医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma 期刊论文 JOURNAL OF THORACIC DISEASE, 2018, 卷号: 10, 期号: 1 作者:  Zhao, Mengnan;  Zhan, Cheng;  Li, Ming;  Yang, Xiaodong;  Yang, Xinyu 收藏  |  浏览/下载：17/0  |  提交时间：2019/12/05 Lung adenocarcinoma  epidermal growth factor receptor (EGFR)  v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)  human epidermal growth factor receptor 2 (HER2)  programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1)   Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab 期刊论文 ONCOTARGET, 2017, 卷号: 8, 期号: 34 作者:  Ding, Jinhua;  Yang, Yinlong;  Jiang, Li;  Wu, Weizhu;  Shao, Zhiming 收藏  |  浏览/下载：6/0  |  提交时间：2019/12/05 breast cancer  neoadjuvant chemotherapy  human epidermal growth factor receptor 2 (HER2)  Ki67  pathological complete response (pCR)   Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis 期刊论文 BREAST CANCER, 2016, 卷号: 23, 期号: 5 作者:  Zhang, Qian;  Chen, Jian;  Yu, Xiaoli;  Cai, Gang;  Yang, Zhaozhi 收藏  |  浏览/下载：6/0  |  提交时间：2019/12/05 Breast cancer  Brain metastasis  Human epidermal growth factor receptor 2 (HER2)-positive breast cancer  Whole-brain radiotherapy  Survival   Outcomes of re-treatment with first-line Trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant Trastuzumab: A prospective multicenter study 期刊论文 ONCOTARGET, 2016, 卷号: 7, 期号: 31 作者:  Xu, Binghe;  Hu, Xichun;  Zheng, Hong;  Wang, Xiaojia;  Zhang, Qingyuan 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/06 trastuzumab  human epidermal growth factor receptor 2 (HER2)  metastatic breast cancer  (Neo)adjuvant trastuzumab  relapse  re-treatment